Transfusion Medicine Reviews
Volume 22, Issue 3 , Pages 188-201 , July 2008

Toward a Molecular Explanation for Cross-presentation of Antigens to the Immune System

  • Bernard Khor
    • ,
  • Robert S. Makar

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Robert S. Makar, Blood Transfusion Service, 55 Fruit St, GRJ2-206C Boston, MA.

References 

  1. Kolb HJ. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties. Vox Sang. 1998;74(Suppl 2):321–329
  2. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041–2050
  3. Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433–444
  4. Porter DL, Collins RH, Shpilberg O, et al. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. Biol Blood Marrow Transplant. 1999;5:253–261
  5. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5:296–306
  6. Gilboa E. The promise of cancer vaccines. Nat Rev Cancer. 2004;4:401–411
  7. Lu W, Arraes LC, Ferreira WT, et al. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med. 2004;10:1359–1365
  8. Berke G. The CTL's kiss of death. Cell. 1995;81:9–12
  9. Abbas AK, Lichtman AH. In: Cellular and molecular immunology. (ed 5). Philadelphia: Elsevier; 2005;p. 81–104
  10. Wolf PR, Ploegh HL. How MHC class II molecules acquire peptide cargo: Biosynthesis and trafficking through the endocytic pathway. Annu Rev Cell Dev Biol. 1995;11:267–306
  11. Watts C. The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules. Nat Immunol. 2004;5:685–692
  12. Kloetzel PM. Generation of major histocompatibility complex class I antigens: Functional interplay between proteasomes and TPPII. Nat Immunol. 2004;5:661–669
  13. Rock KL, York IA, Goldberg AL. Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat Immunol. 2004;5:670–677
  14. Heath WR, Carbone FR. Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol. 2001;1:126–134
  15. Jones CA, Fernandez M, Herc K, et al. Herpes simplex virus type 2 induces rapid cell death and functional impairment of murine dendritic cells in vitro. J Virol. 2003;77:11139–11149
  16. Gredmark S, Soderberg-Naucler C. Human cytomegalovirus inhibits differentiation of monocytes into dendritic cells with the consequence of depressed immunological functions. J Virol. 2003;77:10943–10956
  17. Beatty PR, Stephens RS. CD8+ T lymphocyte–mediated lysis of Chlamydia-infected L cells using an endogenous antigen pathway. J Immunol. 1994;153:4588–4595
  18. Starnbach MN, Bevan MJ. Cells infected with Yersinia present an epitope to class I MHC–restricted CTL. J Immunol. 1994;153:1603–1612
  19. Zwickey HL, Potter TA. Peptide epitopes from noncytosolic Listeria monocytogenes can be presented by major histocompatibility complex class I molecules. Infect Immun. 1996;64:1870–1872
  20. Bevan MJ. Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming. J Immunol. 1976;117:2233–2238
  21. Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med. 1976;143:1283–1288
  22. Bevan MJ. Cross-priming. Nat Immunol. 2006;7:363–365
  23. Rock KL, Shen L. Cross-presentation: Underlying mechanisms and role in immune surveillance. Immunol Rev. 2005;207:166–183
  24. Shen L, Rock KL. Priming of T cells by exogenous antigen cross-presented on MHC class I molecules. Curr Opin Immunol. 2006;18:85–91
  25. Rock KL, Gamble S, Rothstein L. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science. 1990;249:918–921
  26. Grant EP, Rock KL. MHC class I–restricted presentation of exogenous antigen by thymic antigen-presenting cells in vitro and in vivo. J Immunol. 1992;148:13–18
  27. Rock KL, Rothstein L, Gamble S, et al. Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules. J Immunol. 1993;150:438–446
  28. Kovacsovics-Bankowski M, Clark K, Benacerraf B, et al. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci U S A. 1993;90:4942–4946
  29. Shen Z, Reznikoff G, Dranoff G, et al. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol. 1997;158:2723–2730
  30. Heit A, Huster KM, Schmitz F, et al. CpG-DNA aided cross-priming by cross-presenting B cells. J Immunol. 2004;172:1501–1507
  31. Hon H, Oran A, Brocker T, et al. B lymphocytes participate in cross-presentation of antigen following gene gun vaccination. J Immunol. 2005;174:5233–5242
  32. Tobian AA, Harding CV, Canaday DH. Mycobacterium tuberculosis heat shock fusion protein enhances class I MHC cross-processing and -presentation by B lymphocytes. J Immunol. 2005;174:5209–5214
  33. Potter NS, Harding CV. Neutrophils process exogenous bacteria via an alternate class I MHC processing pathway for presentation of peptides to T lymphocytes. J Immunol. 2001;167:2538–2546
  34. Tvinnereim AR, Hamilton SE, Harty JT. Neutrophil involvement in cross-priming CD8+ T cell responses to bacterial antigens. J Immunol. 2004;173:1994–2002
  35. Beauvillain C, Delneste Y, Scotet M, et al. Neutrophils efficiently cross-prime naive T cells in vivo. Blood. 2007;110:2965–2973
  36. Limmer A, Ohl J, Kurts C, et al. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med. 2000;6:1348–1354
  37. Bagai R, Valujskikh A, Canaday DH, et al. Mouse endothelial cells cross-present lymphocyte-derived antigen on class I MHC via a TAP1- and proteasome-dependent pathway. J Immunol. 2005;174:7711–7715
  38. Pozzi LA, Maciaszek JW, Rock KL. Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells. J Immunol. 2005;175:2071–2081
  39. Norbury CC, Malide D, Gibbs JS, et al. Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo. Nat Immunol. 2002;3:265–271
  40. Jung S, Unutmaz D, Wong P, et al. In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity. 2002;17:211–220
  41. Trombetta ES, Ebersold M, Garrett W, et al. Activation of lysosomal function during dendritic cell maturation. Science. 2003;299:1400–1403
  42. Savina A, Jancic C, Hugues S, et al. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell. 2006;126:205–218
  43. Delamarre L, Pack M, Chang H, et al. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science. 2005;307:1630–1634
  44. Ackerman AL, Kyritsis C, Tampe R, et al. Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells. Nat Immunol. 2005;6:107–113
  45. Ackerman AL, Giodini A, Cresswell P. A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells. Immunity. 2006;25:607–617
  46. Villadangos JA, Heath WR, Carbone FR. Outside looking in: The inner workings of the cross-presentation pathway within dendritic cells. Trends Immunol. 2007;28:45–47
  47. Storni T, Bachmann MF. Loading of MHC class I and II presentation pathways by exogenous antigens: A quantitative in vivo comparison. J Immunol. 2004;172:6129–6135
  48. Banchereau J, Pulendran B, Steinman R, et al. Will the making of plasmacytoid dendritic cells in vitro help unravel their mysteries?. J Exp Med. 2000;192:F39–F44
  49. Guermonprez P, Valladeau J, Zitvogel L, et al. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002;20:621–667
  50. Smith CM, Belz GT, Wilson NS, et al. Cutting edge: conventional CD8 alpha+ dendritic cells are preferentially involved in CTL priming after footpad infection with herpes simplex virus-1. J Immunol. 2003;170:4437–4440
  51. Allan RS, Smith CM, Belz GT, et al. Epidermal viral immunity induced by CD8 alpha+ dendritic cells but not by Langerhans cells. Science. 2003;301:1925–1928
  52. Belz GT, Smith CM, Eichner D, et al. Cutting edge: conventional CD8 alpha+ dendritic cells are generally involved in priming CTL immunity to viruses. J Immunol. 2004;172:1996–2000
  53. den Haan JM, Bevan MJ. Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(−) dendritic cells in vivo. J Exp Med. 2002;196:817–827
  54. den Haan JM, Lehar SM, Bevan MJ. CD8(+) but not CD8(−) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med. 2000;192:1685–1696
  55. Belz GT, Behrens GM, Smith CM, et al. The CD8 alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J Exp Med. 2002;196:1099–1104
  56. Pooley JL, Heath WR, Shortman K. Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8− dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells. J Immunol. 2001;166:5327–5330
  57. Schnorrer P, Behrens GM, Wilson NS, et al. The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proc Natl Acad Sci U S A. 2006;103:10729–10734
  58. Carbone FR, Belz GT, Heath WR. Transfer of antigen between migrating and lymph node-resident DCs in peripheral T-cell tolerance and immunity. Trends Immunol. 2004;25:655–658
  59. Villadangos JA, Heath WR. Life cycle, migration and antigen presenting functions of spleen and lymph node dendritic cells: limitations of the Langerhans cells paradigm. Semin Immunol. 2005;17:262–272
  60. Belz GT, Smith CM, Kleinert L, et al. Distinct migrating and nonmigrating dendritic cell populations are involved in MHC class I–restricted antigen presentation after lung infection with virus. Proc Natl Acad Sci U S A. 2004;101:8670–8675
  61. Allan RS, Waithman J, Bedoui S, et al. Migratory dendritic cells transfer antigen to a lymph node–resident dendritic cell population for efficient CTL priming. Immunity. 2006;25:153–162
  62. Shi Y, Rock KL. Cell death releases endogenous adjuvants that selectively enhance immune surveillance of particulate antigens. Eur J Immunol. 2002;32:155–162
  63. Probst HC, Tschannen K, Odermatt B, et al. Histological analysis of CD11c-DTR/GFP mice after in vivo depletion of dendritic cells. Clin Exp Immunol. 2005;141:398–404
  64. Shen L, Rock KL. Cellular protein is the source of cross-priming antigen in vivo. Proc Natl Acad Sci U S A. 2004;101:3035–3040
  65. Wolkers MC, Brouwenstijn N, Bakker AH, et al. Antigen bias in T cell cross-priming. Science. 2004;304:1314–1317
  66. Norbury CC, Basta S, Donohue KB, et al. CD8+ T cell cross-priming via transfer of proteasome substrates. Science. 2004;304:1318–1321
  67. Basta S, Stoessel R, Basler M, et al. Cross-presentation of the long-lived lymphocytic choriomeningitis virus nucleoprotein does not require neosynthesis and is enhanced via heat shock proteins. J Immunol. 2005;175:796–805
  68. Serna A, Ramirez MC, Soukhanova A, et al. Cutting edge: efficient MHC class I cross-presentation during early vaccinia infection requires the transfer of proteasomal intermediates between antigen donor and presenting cells. J Immunol. 2003;171:5668–5672
  69. Udono H, Srivastava PK. Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med. 1993;178:1391–1396
  70. Srivastava PK, Udono H, Blachere NE, et al. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics. 1994;39:93–98
  71. Suto R, Srivastava PK. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science. 1995;269:1585–1588
  72. Berwin B, Rosser MF, Brinker KG, et al. Transfer of GRP94(Gp96)-associated peptides onto endosomal MHC class I molecules. Traffic. 2002;3:358–366
  73. Singh-Jasuja H, Toes RE, Spee P, et al. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J Exp Med. 2000;191:1965–1974
  74. Binder RJ, Blachere NE, Srivastava PK. Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. J Biol Chem. 2001;276:17163–17171
  75. Blachere NE, Li Z, Chandawarkar RY, et al. Heat shock protein–peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med. 1997;186:1315–1322
  76. Kurotaki T, Tamura Y, Ueda G, et al. Efficient cross-presentation by heat shock protein 90–peptide complex–loaded dendritic cells via an endosomal pathway. J Immunol. 2007;179:1803–1813
  77. Binder RJ, Srivastava PK. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat Immunol. 2005;6:593–599
  78. Zheng H, Li Z. Cutting edge: cross-presentation of cell-associated antigens to MHC class I molecule is regulated by a major transcription factor for heat shock proteins. J Immunol. 2004;173:5929–5933
  79. Norbury CC, Hewlett LJ, Prescott AR, et al. Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Immunity. 1995;3:783–791
  80. Harding CV, Song R. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J Immunol. 1994;153:4925–4933
  81. Carbone FR, Bevan MJ. Class I–restricted processing and presentation of exogenous cell-associated antigen in vivo. J Exp Med. 1990;171:377–387
  82. Li M, Davey GM, Sutherland RM, et al. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo. J Immunol. 2001;166:6099–6103
  83. Cresswell P, Ackerman AL, Giodini A, et al. Mechanisms of MHC class I–restricted antigen processing and cross-presentation. Immunol Rev. 2005;207:145–157
  84. Kovacsovics-Bankowski M, Rock KL. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science. 1995;267:243–246
  85. Sigal LJ, Crotty S, Andino R, et al. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature. 1999;398:77–80
  86. Rodriguez A, Regnault A, Kleijmeer M, et al. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol. 1999;1:362–368
  87. Gagnon E, Duclos S, Rondeau C, et al. Endoplasmic reticulum-mediated phagocytosis is a mechanism of entry into macrophages. Cell. 2002;110:119–131
  88. Garin J, Diez R, Kieffer S, et al. The phagosome proteome: Insight into phagosome functions. J Cell Biol. 2001;152:165–180
  89. Oh YK, Harding CV, Swanson JA. The efficiency of antigen delivery from macrophage phagosomes into cytoplasm for MHC class I-restricted antigen presentation. Vaccine. 1997;15:511–518
  90. Ackerman AL, Cresswell P. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol. 2004;5:678–684
  91. Guermonprez P, Saveanu L, Kleijmeer M, et al. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature. 2003;425:397–402
  92. Houde M, Bertholet S, Gagnon E, et al. Phagosomes are competent organelles for antigen cross-presentation. Nature. 2003;425:402–406
  93. Ackerman AL, Kyritsis C, Tampe R, et al. Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc Natl Acad Sci U S A. 2003;100:12889–12894
  94. Touret N, Paroutis P, Terebiznik M, et al. Quantitative and dynamic assessment of the contribution of the ER to phagosome formation. Cell. 2005;123:157–170
  95. Rock KL. Exiting the outside world for cross-presentation. Immunity. 2006;25:523–525
  96. Song R, Harding CV. Roles of proteasomes, transporter for antigen presentation (TAP), and beta 2-microglobulin in the processing of bacterial or particulate antigens via an alternate class I MHC processing pathway. J Immunol. 1996;156:4182–4190
  97. Shen L, Sigal LJ, Boes M, et al. Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo. Immunity. 2004;21:155–165
  98. Pfeifer JD, Wick MJ, Roberts RL, et al. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature. 1993;361:359–362
  99. Campbell DJ, Serwold T, Shastri N. Bacterial proteins can be processed by macrophages in a transporter associated with antigen processing-independent, cysteine protease-dependent manner for presentation by MHC class I molecules. J Immunol. 2000;164:168–175
  100. Wick MJ, Pfeifer JD. Major histocompatibility complex class I presentation of ovalbumin peptide 257-264 from exogenous sources: Protein context influences the degree of TAP-independent presentation. Eur J Immunol. 1996;26:2790–2799
  101. Bachmann MF, Oxenius A, Pircher H, et al. TAP1-independent loading of class I molecules by exogenous viral proteins. Eur J Immunol. 1995;25:1739–1743
  102. Stober D, Trobonjaca Z, Reimann J, et al. Dendritic cells pulsed with exogenous hepatitis B surface antigen particles efficiently present epitopes to MHC class I–restricted cytotoxic T cells. Eur J Immunol. 2002;32:1099–1108
  103. Norbury CC, Princiotta MF, Bacik I, et al. Multiple antigen-specific processing pathways for activating naive CD8+ T cells in vivo. J Immunol. 2001;166:4355–4362
  104. Ruedl C, Storni T, Lechner F, et al. Cross-presentation of virus-like particles by skin-derived CD8(−) dendritic cells: A dispensable role for TAP. Eur J Immunol. 2002;32:818–825
  105. Lizee G, Basha G, Tiong J, et al. Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain. Nat Immunol. 2003;4:1065–1073
  106. Burgdorf S, Lukacs-Kornek V, Kurts C. The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation. J Immunol. 2006;176:6770–6776
  107. Imai J, Hasegawa H, Maruya M, et al. Exogenous antigens are processed through the endoplasmic reticulum-associated degradation (ERAD) in cross-presentation by dendritic cells. Int Immunol. 2005;17:45–53
  108. Saveanu L, van Endert P. Dendritic cells: open for presentation business. Nat Immunol. 2005;6:7–8
  109. Burgdorf S, Kautz A, Bohnert V, et al. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science. 2007;316:612–616
  110. Monu N, Trombetta ES. Cross-talk between the endocytic pathway and the endoplasmic reticulum in cross-presentation by MHC class I molecules. Curr Opin Immunol. 2007;19:66–72
  111. Neijssen J, Herberts C, Drijfhout JW, et al. Cross-presentation by intercellular peptide transfer through gap junctions. Nature. 2005;434:83–88
  112. Mendoza-Naranjo A, Saez PJ, Johansson CC, et al. Functional gap junctions facilitate melanoma antigen transfer and cross-presentation between human dendritic cells. J Immunol. 2007;178:6949–6957
  113. Delamarre L, Holcombe H, Mellman I. Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J Exp Med. 2003;198:111–122
  114. Gil-Torregrosa BC, Lennon-Dumenil AM, Kessler B, et al. Control of cross-presentation during dendritic cell maturation. Eur J Immunol. 2004;34:398–407
  115. West MA, Wallin RP, Matthews SP, et al. Enhanced dendritic cell antigen capture via Toll-like receptor–induced actin remodeling. Science. 2004;305:1153–1157
  116. Wilson NS, Behrens GM, Lundie RJ, et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol. 2006;7:165–172
  117. Weck MM, Grunebach F, Werth D, et al. TLR ligands differentially affect uptake and presentation of cellular antigens. Blood. 2007;109:3890–3894
  118. Stubbs AC, Martin KS, Coeshott C, et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med. 2001;7:625–629
  119. Lu Y, Bellgrau D, Dwyer-Nield LD, et al. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res. 2004;64:5084–5088
  120. Haller AA, Lauer GM, King TH, et al. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine. 2007;25:1452–1463
  121. Davey GM, Kurts C, Miller JF, et al. Peripheral deletion of autoreactive CD8 T cells by cross presentation of self-antigen occurs by a Bcl-2-inhibitable pathway mediated by Bim. J Exp Med. 2002;196:947–955
  122. Blankenstein T, Schuler T. Cross-priming versus cross-tolerance: Are two signals enough?. Trends Immunol. 2002;23:171–173

PII: S0887-7963(08)00013-8

doi: 10.1016/j.tmrv.2008.02.002

Transfusion Medicine Reviews
Volume 22, Issue 3 , Pages 188-201 , July 2008

Article Tools

* Image Usage & Resolution